Cellyan Biotechnology held extraordinary shareholder meeting, quorum reached

• Cellyan Biotechnology held an extraordinary general meeting of shareholders on Sept. 21, 2026.
• Shareholders backed a 1-for-20 consolidation of Class A and Class B ordinary shares, subject to Nasdaq confirmation or no objection.
• The plan sets par value at US$0.02 per share, eliminates fractional shares via rounding up to one share.
• Investors also adopted a fifth amended memorandum and articles, contingent on the consolidation becoming effective.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellyan Biotechnology Co. Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-102385), on September 23, 2026, and is solely responsible for the information contained therein.